Rappel de ARCHITECT / Prolactin Calibrators

Selon L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), ce/cet/cette rappel concerne un dispositif en/au/aux/à France qui a été fabriqué par ABBOTT DIAGNOSTIC.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • Date
    2002-06-18
  • Pays de l'événement
  • Source de l'événement
    ANSM
  • URL de la source de l'événement
  • Notes / Alertes
    French data is current through early September 2018. All of the data comes from L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and France.
  • Notes supplémentaires dans les données
  • Action
    ABBOTT DIAGNOSTIC withdraws batches 76916M300 (per 31.08.02) and 84229M100 (per 28.11.02) from the market for the in vitro diagnostic medical device called ARCHITECT / Prolactin Calibrators - ref. 6C27-01 and lot 76926M300 (per.25.07.02) of the ARCHITECT device / Prolactin Controls - ref. 6C27-10, following a lowering of the prolactin concentration leading to an increase in patient results and controls. As a result: no medical impact insofar as the controls identify the drift of the results; only the above-mentioned control lot may not reveal this drift, in which case the clinical impact is not considered significant. These devices allow the determination of prolactin in serum and human plasma, on the ARCHITECT automaton .

Device

  • Modèle / numéro de série
  • Description du dispositif
    in-vitro_medical_device
  • Manufacturer

Manufacturer

  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    LAANSM